Aptinyx

APTX

Tags: US Healthcare Biotechnology

Aptinyx Price (APTX)

Stock Price

Low: Year Low

High: Year High

Market Cap

Fetching Data...

Enterprise Value

Fetching Data...

Shares Outstanding

67,716,000

(0.7379)%

Market Cap of Aptinyx (APTX)

Market cap:

As of , APTX has a market cap of . This makes APTX the 5239th most valuable company in the US by market cap. Market capitalization, or market cap, is the total value of a company's outstanding shares of stock, calculated by multiplying the current stock price by the total number of shares.

Year

Beginning Of Year

End Of Year

YOY Change

Community Sentiment 0 votes

↑ 0% ↓ 0%

Description

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase II/b clinical trial to tr... Read More

Sector: Healthcare

Previous Close Fetching Data...
Range $0.009-0.72
Market Cap 0.00
Enterprise Value No Data
Avg Volume Fetching Data...
P/E Ratio Fetching Data...
Dividend Yield Fetching Data...

Industry: Biotechnology

ceo: Mr. Craig R. Jalbert CIRA
IPO Date: June, 21, 2018
Country: US
Currency: USD
Headquaters: Evanston, IL
Employees: 12

- Revenue from each product or segment:

Product or Segment	Value:	% - Total	Last 3Y:

- Revenue by Region

Product or Segment	Value:	% - Total	Last 3Y: